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Abstract
Targeting apoptosis in the ischemic penumbra is a rational therapeutic approach for restricting cerebral infarct volume after 
clinical stroke. The present work explored the capability of the obestatin peptide, as a novel approach to inhibit apoptotic 
signaling cascades on PC12 cells. According to the results, obestatin treatment significantly reduced nutrient deprivation-
induced apoptotic cell death. The protective effects were related to the regulation of the anti-apoptotic protein, BCL-2, 
and the apoptotic protein caspase-3. This encompasses the control of apoptosis by the interplay between Akt, ERK1/2 and 
AMPK signaling pathways. The activation of Akt and AMPK was concomitant with the phosphorylation of their downstream 
targets, GSK3 and ACC, respectively. Besides, obestatin also causes FoxO1 nuclear export supporting the prevention of the 
apoptosome formation. The concurrent activation of Akt and AMPK by obestatin via the GPR39 receptor, supports a role 
for this system in the balance concerning the catabolic and the anabolic signaling to sustain cellular function and viability. 
Furthermore, these results provide both an insight into how the obestatin/GPR39 system regulates anti-apoptotic pathways, 
and a framework for ascertaining how this system can be optimally targeted in treatment of brain cell death after stroke.
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Introduction
After a focal ischemic stroke, the reduced blood flow causes 
lesions in the nucleus of the brain tissue leading to the death 
of the necrotic cells. (Lo et al. 2003; Broughton et al. 2009; 
Moskowitz et al. 2010). Surrounding this necrotic core, a 
less affected area of tissue known as ischemic penumbra, 
is still metabolically active, although it remains function-
ally silent due to decreased blood flow. Apoptosis is the 
most relevant mechanism of cell death in the penumbra in 
which both caspase-dependent and caspase-independent 
mechanisms have been described (Yuan and Yankner 2000; 
Uzdensky 2019). In this peri-infarct margin, cells die more 
slowly as the penumbra collapses and the lesion expands 
over time, which potentially allows its recovery in a short 
time frame after the stroke. (Broughton et al. 2009; Moskow-
itz et al. 2010). Indeed, this therapeutic window seems to 
correspond temporarily with the initiation of caspase acti-
vation, whose inhibitors, administered up to that point of 
the protease activation, are able to attenuate ischemic brain 
injury and neurological function (Moskowitz et al. 2010). 
Therefore, targeting apoptotic-like mechanisms provide an 
opportunity for therapeutic focused to limit cerebral infarct 
volume (Dalkara and Moskowitz 2011).
Our previous works on the obestatin/GPR39 system 
demonstrated its key role in the regulation of skeletal mus-
cle repair, supporting it as a promising therapeutic target 
(Gurriarán-Rodríguez et al. 2012, 2015; Santos-Zas et al. 
2016). The 23-amino acid peptide obestatin, originated 
from the precursor polypeptide preproghrelin, controls 
de myogenic program driving anabolic processes within 
the activation of the G protein‐coupled receptor, GPR39 
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(Santos-Zas et al. 2016). Obestatin signaling regulates 
multiple steps of the myogenesis machinery by using G 
protein- and β‐arrestin dependent pathways with ERK1/2 
and AKT activation being the primary effectors, respec-
tively (Santos-Zas et al. 2016). More importantly, obesta-
tin/GPR39 system transforms the identity of the muscle 
fiber, modifying the skeletal muscle phenotype into an 
oxidative profile (Santos-Zas et al. 2017) and counteracts 
deregulations in proteostasis by restoring efficient basal 
homoeostasis (Cid-Diaz et al. 2017).
AKT signaling plays important roles in neuronal sur-
vival, thereby influencing brain function with implications 
in a diverse set of neurological disorders (Manning and 
Toker 2017; Brunet et al. 2001). Thus, it is possible to 
speculate about the neuroprotective effect of the obestatin/
GPR39 system as regulator of AKT-driven anabolic pro-
gram. To test this hypothesis, we evaluated the activation 
of obestatin signaling in PC12 cells in which apoptotic cell 
death was induced by nutrient deprivation. In this work, 
we describe a potential neuroprotective function for the 
obestatin/GPR39 system by inhibition of the apoptotic-
like mechanisms outstanding in ischemic stroke.
Materials and Methods
Materials
All the materials used in this section are listed in Table 1.
Cell Culture
PC-12 cells (ATCC Cat# CRL-1721, RRID:CVCL_0481) 
were cultured on collagen-I-coated plates with RPMI 1640 
containing 10% FBS, 5% heat inactivated HS and 1% GPS. 
Cells were kept at 37 ºC in a humidified atmosphere con-
taining 5%  CO2.
Immunocytochemistry
PC12 cells cultured on collagen-I-coated coverslips (5000 
cells/cm2) were fixed in 96% (v/v) ethanol. Cell samples 
were consecutively incubated with: (1) primary antibody 
(Table  1) in EnVision™ FLEX antibody diluent; (2) 
EnVision™ FLEX peroxidase blocking regent used as 
the detection system; and (3) diaminobenzidine (DAB+) 
chromogenic substrate system. Harris’ hematoxylin was 
used to counterstain the samples.
Proliferation Assay
PC12 cells were seeded on collagen type I-coated 96-well 
plates (5000 cells/cm2) using DMEM with 5% FBS. Upon 
24 h, serum was withdrawn for 18 h and the cells were 
treated or not with obestatin (50–200 nM) for 48 h. The 
cell proliferation was evaluated using CCK8 according to 
the manufacturer’s instructions.
Cell Viability Assays
PC12 cells were seeded as described above at a ratio of 
30,000 cells/cm2 and serum was withdrawn for 16 h. Cells 
were then treated with obestatin (200 nM) in HBSS for 
6 h. Viability was detected using the CCK-8 kit, according 
to the manufacturer’s instructions.
Propidium Iodide Staining
PC12 cells were cultured (5000 cells/cm2) as indicated 
above and treated or not with 200 nM obestatin. Then, 
the cells were fixed (MeOH), washed with citrate buffer 
[0.03 M sodium citrate (pH 7.0)] and then incubated with 
PI. The cell nuclei were counterstained with DAPI. Con-
focal images were obtained with a Leica TCS SPE (Leica 
TCS SPE, RRID:SCR_002140) version 8 confocal micro-
scope. The M2 Manders coefficient (Manders et al. 1993) 
was quantified by the Fiji image processing software (Fiji, 
RRID:SCR_002285) version 2.1.0/1.53c.
Immunoblot Analysis
The protein was obtained after lysing the cells in ice cold 
radioimmunoprecipitation assay (RIPA) buffer as previ-
ously described (Cid-Diaz et al. 2017). The QuantiPro™ 
BCA assay kit was used to quantify the protein concentra-
tion. The proteins were resolved by SDS-PAGE and subse-
quently transferred onto nitrocellulose membranes. Then, 
the membranes were incubated with the corresponding 
antibodies (Table 1). The bands were detected by ECL and 
digitalized using a ChemiDoc MP system (BioRad Labo-
ratories; RRID:SCR_008426). Finally, the protein bands 
were analyzed by the Fiji image processing software.
Immunofluorescence
PC12 cells were seeded as indicated for the cell viabil-
ity assay. Upon serum withdrawn for 16  h, the cells 
were then treated or not with 200 nM obestatin in HBSS 
(6 h). Immunofluorescence was carried out as previously 
described (Cid-Diaz et al. 2017). Anti-FoxO1 antibody 
was used as primary antibody, using DAPI to visualize the 
cell nuclei. Confocal images were obtained with a Leica 
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confocal microscope. Pearson coefficient was quantified 
by Fiji image software.
Data Analysis
The data were analyzed with the GraphPad Prism process-
ing program (GraphPad Prism, RRID:SCR_002798) ver-
sion 8.2.1. The results are displayed as mean ± SEM. The 
statistical significance among groups was determined with 
Mann–Whitney test or one-way ANOVA post hoc test (Fish-
er’s Least Significant Difference). The asterisks * or **, rep-
resent a P value of < 0.05 or < 0.01, respectively.
Results
Obestatin Enhances PC12 Cell Proliferation
The capability of obestatin/GPR39 system as a switch 
between cell survival and death was addressed in PC12 
cells, a cell line widely used to study neuroprotective 
effects of drugs (de los Rios et al. 2018). We first evalu-
ated the presence of obestatin and GPR39 in PC12 cells 
by immunocytochemistry. Intense GPR39 positivity was 
observed associated to the plasma membrane whereas 
an also strong but more diffuse immunostaining was 
detected for obestatin in the same area (Fig. 1a). We then 
defined a dose-rate effect for obestatin (50–200 nM) on 
Table 1  Materials used in the analyses performed in this work
Conc. concentration, IF immunofluorescence, IHC immunohistochemistry, WB Western blot, RTU ready to use
Antibodies Use Conc. Details
Obestatin IHC 1:100 Abcam Cat# ab41704, RRID:AB_776891
GPR39 IHC 1:500 Abcam Cat# ab39227, RRID:AB_941685
ß-actin WB 1:1000 Santa Cruz Biotechnology Cat# sc-7210, RRID:AB_2223518
BCL-2 WB RTU Dako, RRID:SCR_013530; Cat#IS614
Caspase 3 WB 1:1000 Abcam Cat# ab2302, RRID:AB_302962
pERK1/2(T202/Y204) WB 1:1000 Cell Signaling Technology Cat# 9101, RRID:AB_331646
ERK1/2 WB 1:1000 Cell Signaling Technology Cat# 9102, RRID:AB_330744
pGSK3α/ß(S21/9) WB 1:1000 Cell Signaling Technology Cat# 9331, RRID:AB_329830
GSK3α/ß WB 1:1000 Santa Cruz Biotechnology Cat# sc-56913, RRID:AB_783600
pAKT(S473) WB 1:1000 Cell Signaling Technology Cat# 9271, RRID:AB_329825
Akt WB 1:1000 Cell Signaling Technology Cat# 9272, RRID:AB_329827
pAMPKα (T172) WB 1:1000 Cell Signaling Technology Cat# 2535, RRID:AB_331250
AMPKα WB 1:1000 Cell Signaling Technology Cat# 2603, RRID:AB_490795
pACC(S79) WB 1:1000 Cell Signaling Technology Cat# 3661, RRID:AB_330337
α-tubulin WB 1:1000 Santa Cruz Biotechnology Cat# sc-5546, RRID:AB_635001
FoxO1 IF 1:100 Cell Signaling Technology Cat# 2880, RRID:AB_2106495
Materials Details
Rat/mouse obestatin BCN peptides, Cat#OBE-15X1
RPMI 1640 Lonza, RRID:SCR_000377, Cat#12-167F
Foetal bovine serum, FBS Thermo Fisher Scientific, RRID:SCR_008452, Cat#11521851
Horse serum, HS Lonza, RRID:SCR_000377, Cat#14-427F
Penicillin–Streptomycin-Glutamine, GPS Thermo Fisher Scientific, RRID:SCR_008452, Cat#10378016
EnVision™ FLEX antibody diluent Dako, RRID:SCR_013530, Cat#DM830
EnVision™ FLEX peroxidase blocking regent Dako, RRID:SCR_013530, Cat#SM801
3,3′-Diaminobenzidine-tetrahydrochloride, DAB Dako, RRID:SCR_013530, Cat#SM803
Cell Counting Kit-8, CCK8 Dojindo Laboratories, Cat#CK04
Hank’s balanced salt solution, HBSS Thermo Fisher Scientific, RRID:SCR_008452, Cat#24020-091
Propidium iodide, PI Invitrogen Antibodies, RRID:SCR_008410, Cat#P3566
4′,6‐Diamidino‐2‐phenylindole, DAPI Invitrogen Antibodies, RRID:SCR_008410, Cat#D1306
QuantiPro™ BCA Sigma-Aldrich, RRID:SCR_008988, Cat#QPBCA
ECL Western Blotting Substrate Thermo Fisher Scientific, RRID:SCR_008452, Cat#32106
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proliferation of PC12 cell showing its maximal effect at 
200 nM (Fig. 1b).
Obestatin Signaling Protects PC12 Cells 
from Nutrient Deprivation‑Induced Apoptotic Cell 
Death
Incubation of PC12 cells for 6 h under nutrient deprivation 
conditions decreased cell viability, as compared to the control 
Fig. 1  a Immunocytochemical expression of obestatin and GPR39 
(upper and lower panel, respectively) in PC12 cells. b Dose–response 
effect of obestatin on PC12 cell proliferation determined by CCK8 
assay (n = 8 per group). c Dose–response effect of obestatin on cell 
viability evaluated by CCK8 assay in nutrient-deprived PC12 cells 
(n = 6 per group). d Effect of obestatin (200  nM) on cell apoptosis 
evaluated by PI staining in nutrient-deprived PC12 cells. Left panel, 
representative images of PC12 cells stained with PI (red). Nucleus 
were counterstained with DAPI (blue). Right panel, quantification of 
Manders split coefficient (M2). Data were expressed as mean ± SEM. 
Asterisk (*, **) indicates P < 0.05 and P < 0.01 (ANOVA, Fisher’s 
LSD)
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cultures (Fig. 1c). Co-incubation of the PC12-deprived cells 
with a range of obestatin concentrations (50–200 nM) reversed 
this effect (Fig. 1c). Remarkably, the cell death of PC12-
deprived cells under obestatin administration (200 nM), esti-
mated by Manders correlation coefficient between DAPI and 
PI (M2), was decreased to a similar level of those PC12 cells 
without nutrient deprivation conditions (Fig. 1d). At molecular 
level, this result was in line with the changes observed in the 
caspase 3 apoptosis indicator (D’Amelio et al. 2010). Nutri-
ent deprivation conditions promoted caspase 3 activity by a 
synchronized decline of pro-caspase 3 (mw ≅ 30 KDa) and an 
enhancing of caspase 3 levels (mw ≅ 15 KDa) in PC12 cells, 
whereas obestatin treatment (200 nM) clearly reversed the 
deprivation-induced change (Fig. 2a). Furthermore, obestatin-
treated PC12 cells exhibited significant increase of BCL-2, 
an anti-apoptotic protein (Fig. 2a) (Czabotar et al. 2014). The 
concurrent caspase 3 downregulation and BCL-2 upregulation 
pointed to the involvement of the growth promoting Akt-sign-
aling pathway (Manning and Toker 2017). In fact, Akt acti-
vation was observed as an increasing in the phosphorylation 
of its S473 regulatory residue [pAkt(S473)], after obestatin 
treatment (200 nM) compared to PC12-nutrient deprived cells 
(Fig. 2b). The up‐regulation of Akt activity was concomitant 
with an increase in GSK3 phosphorylation at S21/9 (Fig. 2b). 
Furthermore, obestatin markedly promoted ERK1/2 at T202/
Y204 on PC12-deprived cells (Fig. 2c). Strikingly, AMPK 
activation, evaluated by its phosphorylation at the T172 resi-
due, augmented in response to obestatin related to untreated 
PC12-deprived cells (Fig. 2d). This correlated with increased 
phosphorylation of ACC, a downstream AMPK substrate, at 
S79 (Fig. 2d). For these targets, obestatin treatment achieved 
equivalent levels to those reached in control PC12 cells. 
Finally, the endogenous FoxO1 localization was studied by 
immunofluoresecence, and the nuclear to cytoplasmic fluores-
cence ratio was calculated by overlapping coefficient according 
to Pearson. Figure 2e shows that Fox1 was located mainly in 
the nucleus in PC12-deprived cells; however, obestatin treat-
ment causes Fox1 translocation to cytoplasm, a similar pattern 
to that observed in untreated control cells. Similar results were 
observed when analyzing the Pearson coefficient, detecting a 
remarkable reduction for this coefficient in obestatin-treated 
cells compared to PC12-deprived cells (Fig. 2e). The obtained 
results demonstrate the function of the obestatin/GPR39 sys-
tem in the activation of the antiapoptotic program, a function 
that is finely regulated by the interaction of the Akt, ERK1/2- 
and AMPK-signaling axes.
Discussion
The characteristics of obestatin signaling to prevent cell 
death offers a promising strategy to address nerve dam-
age and slow down any degeneration of nervous system. 
The main finding of this work is the neuroprotective action 
exerted by the obestatin/GPR39 system, since obestatin con-
siderably reduces the cell death induced by nutrients defi-
ciency in PC12 cells. These capabilities are due to a fine tun-
ing of the Akt signaling pathway as well as its downstream 
target, BCL-2, in concert with the inhibition of cleaved-cas-
pase 3 expression. This further includes the simultaneous 
control of the ERK1/2 pathway encompassing a series of 
effector proteins, which eventually tip the outcome in favor 
of cell survival. Strikingly, AMPK responds to obestatin, 
and its activation was independent of the Akt activity. Thus, 
cellular homeostasis of metabolism and growth is exquisitely 
controlled by the obestatin/GPR39 system by coordination 
of Akt, ERK1/2 and AMPK signaling cascades.
Akt and ERK1/2 transduce survival signals in response 
to obestatin (Santo-Zas et al. 2016). It has been described 
that ERK1/2 activation causes inhibition of caspase 9 activ-
ity through its phosphorylation and, as a consequence, the 
inhibition of caspase 3 processing, which ultimately inhibits 
apoptosis (Allan et al. 2003). On the other hand, the activa-
tion of Akt is associated with the restraint of the apoptotic 
process at different stages of its signaling cascade, including 
the braking of the sensors and effectors of the mitochon-
drial apoptotic pathway at molecular, transcriptional and 
metabolic levels (Manning and Toker 2017). Akt regulates 
FoxO1 transcriptional activity by site-specific phospho-
rylation and nuclear export (Matsuzaki et al. 2003; Aoki 
et al. 2004). Indeed, FoxO1 inactivation up-regulates the 
antiapoptotic protein BCL2, which avoids cytochrome c 
output from the mitochondria, the apoptosome formation 
and downstream caspase (Czabotar et al. 2014; Wang et al. 
2018). Therefore, both mechanisms demonstrate overlapping 
features that impact on effector caspases, i.e. caspase-3, that 
target substrates to dismantle the cell (D’Amelio et al. 2010).
Paradoxically, this study reveals concurrent activation of 
Akt and AMPK by the obestatin/GPR39 system, two path-
ways typically considered as antagonistic signaling events. 
The coupling between the anabolic and catabolic functions 
appears to sustain core anabolic functions required for cell 
viability. Consistent with this, previous studies described 
active catabolic machinery in the context of active anabolic 
signaling in which augment their respective functions and 
facilitate the mass synthesis of secretory proteins (Narita 
et al. 2011; Kaur and Debnath 2015; Dalle-Pezze et al. 
2016). Thus, this study provides an unexpected cellular task 
for the obestatin/GPR39 system in the regulation of cata-
bolic processes enabling cells to maintain the correct func-
tioning and the health of the cells (Fig. 2f). Further insight 
will be required to clarify the precise molecular features 
involved in this unconventional pathway.
At this point, we conclude that the concurrent activa-
tion of catabolic and anabolic pathways by the obestatin/
GPR39 system promotes cell survival while inhibiting death 
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effectors. These findings suggest that proper co-manipula-
tion of these signaling pathways denote a potential strategy 
to limit neuronal damage.
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Fig. 2  Analysis by immunoblots of BCL-2 and caspase 3 (a), phos-
phorylation of Akt at S473 [pAkt(S473)] and GSK3a/b at S21/9 
[pGSK3 a/b(S21/9)] (b), phosphorylation of ERK1/2 at T202/Y204 
[pERK1/2(T202/Y204)] (c), and phosphorylation of AMPKa at 
T172 [p AMPKa(T172)] and ACC at S79 [pACC(S79)] (d), in con-
trol, nutrient-deprived (ND) and obestatin-treated (200 nM) nutrient-
deprived (ND + OB) PC12 cells. e Left panel, immunofluorescence 
detection of FoxO1 in control, ND and ND + OB PC12 cells. The 
cellular localization was determined using fluorescence microscopy 
using DAPI to label cell nuclei. Right panel, quantification of Pearson 
coefficient. Data were expressed as mean ± SEM (n = 3 per group). 
(***, P < 0.001; ANOVA, Fisher’s LSD). f Schematic diagram of the 
crosstalk between the catabolic and the anabolic processes activated 
by obestatin/GPR39 signaling. From a to d, data were expressed as 
mean ± SEM (n = 6 per group). Immunoblots are representative of the 
mean value. Asterisk (*) denotes P < 0.05 (Mann–Whitney test)
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